Search Results - "POWELL, JAMES R."

Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial by Pajewski, Nicholas M, Williamson, Jeff D, Applegate, William B, Berlowitz, Dan R, Bolin, Linda P, Chertow, Glenn M, Krousel-Wood, Marie A, Lopez-Barrera, Nieves, Powell, James R, Roumie, Christianne L, Still, Carolyn, Sink, Kaycee M, Tang, Rocky, Wright, Clinton B, Supiano, Mark A

“…The Systolic Blood Pressure Intervention Trial (SPRINT) is testing whether a lower systolic blood pressure (BP) target of 120 mm Hg leads to a reduction in…”
Get full text

Bekenstein’s Entropy Bound-Particle Horizon Approach to Avoid the Cosmological Singularity by Powell, James R., Lopez-Mobilia, Rafael, Matzner, Richard A.

“…The cosmological singularity of infinite density, temperature, and spacetime curvature is the classical limit of Friedmann’s general relativity solutions…”
Get full text

Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial by Still, Carolyn H, Rodriguez, Carlos J, Wright, Jackson T, Craven, Timothy E, Bress, Adam P, Chertow, Glenn M, Whelton, Paul K, Whittle, Jeffrey C, Freedman, Barry I, Johnson, Karen C, Foy, Capri G, He, Jiang, Kostis, John B, Lash, James P, Pedley, Carolyn F, Pisoni, Roberto, Powell, James R, Wall, Barry M

“…Abstract BACKGROUND The Systolic Blood Pressure Intervention Trial (SPRINT) showed that targeting a systolic blood pressure (SBP) of ≤ 120 mm Hg (intensive…”
Get full text

Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials by Okunrintemi, Victor, Mishriky, Basem M., Powell, James R., Cummings, Doyle M.

“…Dapagliflozin is a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor that has recently been shown to reduce the incidence of reported episodes of atrial…”
Get full text

Implementing the association between rosacea, hypertension, and dyslipidemia in clinical practice by Pona, Adrian, Labbe, Jonathan, Afriyie, Felix, Jiwani, Rahim, Powell, James R.

Get full text

A meta‐analysis of randomized controlled trials evaluating sodium‐glucose co‐transporter 2 inhibitors and incidental atrial fibrillation—Is there a true benefit? by Mishriky, Basem M., Cummings, Doyle M., Powell, James R.

Get full text

Reproducible and Interpretable Machine Learning-Based Radiomic Analysis for Overall Survival Prediction in Glioblastoma Multiforme by Duman, Abdulkerim, Sun, Xianfang, Thomas, Solly, Powell, James R, Spezi, Emiliano

“…To develop and validate an MRI-based radiomic model for predicting overall survival (OS) in patients diagnosed with glioblastoma multiforme (GBM), utilizing a…”
Get full text

GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trials by Hamedi, Zahra, Mishriky, Basem M., Okunrintemi, Victor, Powell, James R., Cummings, Doyle M.

Get full text

Diabetes-Related Microvascular Complications – A Practical Approach by Mishriky, Basem M., Cummings, Doyle M., Powell, James R.

“…Diabetes-related microvascular complications include diabetic neuropathy (eg, diabetic symmetric polyneuropathy (DSPN), cardiac autonomic neuropathy,…”
Get full text

Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis by Mishriky, Basem M., Powell, James R., Wittwer, Jennifer A., Chu, Jennifer X., Sewell, Kerry A., Wu, Qiang, Cummings, Doyle M.

“…Aims While recent cardiovascular safety trials (CVST) concerning newer diabetes medications included mostly white participants, results are being generalized…”
Get full text

102-LB: Cumulative Probability of Mortality among Non-Hispanic Black Compared with Non-Hispanic White Individuals with Type 2 Diabetes on Empagliflozin (EMPA-AA)—Real-World Data by MISHRIKY, BASEM M., CUMMINGS, DOYLE M., FU, YUANYUAN, HALLADAY, JACQUIE, JONES, WILLIAM S., BOAN, ANDREA D., JONES BERKELEY, SARA, PATIL, SHIVAJIRAO P., POWELL, JAMES R., ADAMS, ALYSSA, IRISH, WILLIAM

“…Authors 1, 2 & 11 participated equally. Given the underrepresentation of minorities in the CV outcome trials, guidelines encouraged investigating…”
Get full text

Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data by Mishriky, Basem M., Cummings, Doyle M., Fu, Yuanyuan, Halladay, Jacqueline R., Jones, Schuyler, Boan, Andrea D., Jones, Sara, Patil, Shivajirao P., Powell, James R., Adams, Alyssa, Irish, William

“…Aim There are limited data to evaluate hospitalization for heart failure (hHF) in non‐Hispanic Black (hereafter Black) or non‐Hispanic White (hereafter White)…”
Get full text

The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials by Younes, Ahmed M., Mishriky, Basem M., Powell, James R, Cummings, Doyle M

“…•There may be hesitancy in prescribing GLP-1RA in older adults.•GLP-1RAs were associated with lower incidence of MACE regardless of baseline age.•GLP-1RAs…”
Get full text

Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes by Mishriky, Basem M., Cummings, Doyle M., Powell, James R.

“…Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender…”
Get full text

20-LB: Heart Failure Hospitalization among African American Compared with White Individuals with Type 2 Diabetes on Empagliflozin—Real-World Data by MISHRIKY, BASEM M., CUMMINGS, DOYLE M., FU, YUANYUAN, HALLADAY, JACQUIE, JONES, WILLIAM S., BOAN, ANDREA, BERKELEY, SARA JONES, PATIL, SHIVAJIRAO P., POWELL, JAMES R., ADAMS, ALYSSA, IRISH, WILLIAM

“…While African Americans (AA) were underrepresented in the SGLT2i CVOT, the results from those trials were generalized to all, regardless of race. Our goal was…”
Get full text

2390-PUB: A Diabetes Clinic in the Primary Care Setting: A Quality Improvement Initiative in a Teaching Institution—One-Year Data by MISHRIKY, BASEM M., POWELL, JAMES R., HOLOMAN, CARYL E., MIAN, MUNA R.

“…Diabetes remains one of the most common chronic conditions seen in primary care clinics. While it remains one of the toughest quality measures to fulfill, it…”
Get full text

Impact of Intensive Blood Pressure Therapy on Concern about Falling: Longitudinal Results from the Systolic Blood Pressure Intervention Trial (SPRINT) by Berlowitz, Dan R., Foy, Capri, Conroy, Molly, Evans, Gregory W., Olney, Christine M., Pisoni, Roberto, Powell, James R., Gure, Tanya R., Shorr, Ronald I.

“…OBJECTIVES Concern about falling is common among older hypertension patients and could impact decisions to intensify blood pressure therapy. Our aim was to…”
Get full text

2365-PUB: Can Baseline Hemoglobin A1c Help Guide Treatment with an SGLT2i vs. DPP-4i? A Meta-analysis by PAGE, STEPHANIE O., MISHRIKY, BASEM M., UHRIG, JARROD, SEWELL, KERRY, MIAN, MUNA R., POWELL, JAMES R., CUMMINGS, DOYLE M.

“…Both sodium glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are effective drugs known to reduce hemoglobin A1c…”
Get full text

242-OR: Do GLP-1RA and SGLT2i Reduce Cardiovascular Mortality in African-American Patients with Type 2 Diabetes? A Meta-analysis by MISHRIKY, BASEM M., POWELL, JAMES R., WITTWER, JENNIFER A., CHU, JENNIFER X., SEWELL, KERRY, WU, QIANG, CUMMINGS, DOYLE M.

“…While patients enrolled in the cardiovascular safety trials (CVST) for GLP-1RA and SGLT2i were mostly whites, the ADA’s updated recommendations are being…”
Get full text

2363-PUB: The Efficacy of Low vs. High FDA-Approved SGLT2 Inhibitor Dose Compared with DPP-4 Inhibitors: A Meta-analysis by UHRIG, JARROD, MISHRIKY, BASEM M., PAGE, STEPHANIE O., SEWELL, KERRY, POWELL, JAMES R., PATIL, SHIVAJIRAO P., CUMMINGS, DOYLE M.

“…All FDA-approved SGLT2 inhibitors (SGLT2i) are currently available in two doses. While most SGLT2i have demonstrated CV benefit, there may be a difference in…”
Get full text